# Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

> **NCT01741792** · PHASE2 · COMPLETED · sponsor: **Amgen Research (Munich) GmbH** · enrollment: 25 (actual)

## Conditions studied

- Diffuse Large B-cell Lymphoma

## Interventions

- **DRUG:** Blinatumomab

## Key facts

- **NCT ID:** NCT01741792
- **Lead sponsor:** Amgen Research (Munich) GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07
- **Primary completion:** 2014-07
- **Final completion:** 2015-09
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2017-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01741792

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01741792, "Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01741792. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*